



Formulary 2 Updates April 9, 2025

The following drug products were reviewed and acted upon by the CDPHP Pharmacy and Therapeutics Committee for The Formulary 2.

ACA Covered under the Affordable Healthcare Act-no member cost share

MNPA Medical Necessity Prior Authorization

PA Prior authorization required

PD Preventive Drug

QL Quantity Limits Apply

SP Restricted to ConnectRx or CVS Caremark Specialty Pharmacy

ST Step Therapy

Drug	Previous Coverage	Coverage
Alhemo® (concizumab-mtci) subcutaneous injection	New to market	Tier 3, PA (Medical benefit, PA)
Alyftrek™ (vanzacaftor/tezacaftor/deutivacaftor) oral tablets	New to market	Not covered
Bizengri® (zenocutuzunab-zbco) intravenous infusion	New to market	Medical benefit, PA
Crenessity™ (crinecerfont) oral tablets	New to market	Tier 3, PA, QL
Datroway® (datopotamab deruxtecan-dlnk) intravenous infusion	New to market	Medical benefit, PA
Journavx® (suzetrigine) oral tablets	New to market	Tier 3, PA, QL
Kebilidi™ (eladocagene exuparvovec-tneq) Intraputaminal	New to market	Medical benefit, PA
Mercaptopurine oral suspension (generic for Purixan)	New to market	Tier 2, PA, QL
Niktimvo™ (axatilimab-csfr) intravenous infusion	New to market	Medical benefit, PA
Purixan oral suspension (mercaptopurine)	Tier 2	Not covered for new start (current utilizers will be grandfathered)
Tryngolza (olezarsen) Subcutaneous Injection	New to market	Tier 3, PA, QL
Xromi oral solution (hydroxyurea)	New to market	Tier 3, PA, QL